Company Profile

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases, and exploring their potential to provide deep, durable, and potentially curative responses. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate the pathogenic B cells that express disease-causing autoantibodies while sparing normal B cells, leaving the healthy immune system intact. Our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation (CABA™) platform, has applicability across more than two dozen B cell-mediated autoimmune diseases. Using our CABA™ platform, we have discovered and developed five disclosed product candidates, including our lead clinical-stage therapy in development to treat patients with mucosal pemphigus vulgaris. We hold multiple agreements with the University of Pennsylvania and other academic institutions to develop CAAR T cell therapies. Our goal is to leverage our team’s expertise in autoimmunity and engineered T cell therapy and our network of collaborators to rapidly discover and develop our portfolio of CAAR T product candidates.

Latest Presentation

Industry Classifications



Pharmaceutical Preparation Manufacturing (325412)

Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
Anup Marda
Chief Financial Officer

Stern Investor Relations, Inc.
Sarah McCabe

Company Contact
Cabaletta Bio, Inc.
2929 Arch Street
Suite 600
Philadelphia, PA 19104